ArticleInvestigative ophthalmology & visual science2026
Effect of ARHGAP9 on Chemoresistance in High-Risk Advanced Retinoblastoma via the Rac1/β-Catenin/LEF1 Signaling Axis.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Resistance to adjuvant chemotherapy following enucleation continues to drive recurrence and metastasis in high-risk advanced retinoblastoma (RB), posing a major clinical challenge. To identify candidate genes, a previous transcriptomic analysis revealed markedly reduced expression of Rho GTPase-activating protein 9 (ARHGAP9) in the etoposide-resistant Y79/EDR cell line. This study aims to further investigate the effect of ARHGAP9 on chemoresistance in high-risk advanced RB. Methods: Whole-exome sequencing and reduced-representation bisulfite sequencing profiles of eight peripheral blood samples from patients with high-risk advanced RB were analyzed to identify genes with germline genetic or epigenetic alterations associated with RB prognosis. In vitro and in vivo studies on drug responsiveness and molecular mechanisms were conducted in stable ARHGAP9-silenced and ARHGAP9-overexpressing cell lines. Results: ARHGAP9 was identified through peripheral blood-based genomic and epigenomic analyses and further validated via functional study. Functional assays demonstrated that ARHGAP9 knockdown considerably decreased sensitivity to carboplatin and etoposide, whereas its overexpression restored drug responsiveness in vitro and in vivo. Mechanistic analysis indicated that ARHGAP9 downregulation markedly enhanced Ras-related C3 botulinum toxin substrate 1 (Rac1) activity as its catalytic substrate, promoted Rac1-β-catenin interaction, and facilitated their nuclear accumulation. This process induced the formation of lymphoid enhancer-binding factor 1 (LEF1)-β-catenin complex and increased expression of downstream proteins, such as c-Myc, cyclin D1, and Bcl-2, which contribute to chemotherapy resistance in RB. Conclusions: These findings provide mechanistic insights into how ARHGAP9 modulates drug responses via the Rac1/β-catenin/LEF1 signaling axis in RB and suggest that ARHGAP9 warrants further investigation as a candidate prognostic indicator or therapeutic target for advanced high-risk RB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.